Thierry Alquier

Thierry Alquier

Auto-generated profile, based on publicly available information

Thierry Alquier

Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Montréal, Canada

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2005 in Cell Metabolism
Verified
Journal Article
Closed access
BKBarbara B. Kahn
Barbara B. Kahn
TAThierry Alquier
Thierry Alquier
DCDavid Carling
David Carling
DHDavid Grahame Hardie
David Grahame Hardie

17 March 2004 in Nature
Verified
Journal Article
Closed access
PDF file
YMYasuhiko Minokoshi
Yasuhiko Minokoshi
TAThierry Alquier
Thierry Alquier
NFNoboru Furukawa
Noboru Furukawa
YKYoung-Bum Kim
Young-Bum Kim
ALAnna Lee
Anna Lee
BKBarbara B. Kahn
Barbara B. Kahn

1 April 2007 in Diabetes
Verified
Journal Article
Closed access
PDF file
MLMartin G. Latour
Martin G. Latour
TAThierry Alquier
Thierry Alquier
EOElizabeth Oseid
Elizabeth Oseid
CTCaroline Tremblay
Caroline Tremblay
TJThomas L. Jetton
Thomas L. Jetton
VPVincent Poitout
Vincent Poitout
Long-chain fatty acids amplify insulin secretion from the pancreatic β-cell. The G-protein–coupled receptor GPR40 is specifically expressed in β-cells and is activated by fatty acids; however, its role in acute regulation of insulin secretion in vivo remains unclear. To this aim, we generated GPR40 knockout (KO) mice and examined glucose homeostasis, insulin secretion in response to glucose and Intralipid in vivo, and insulin secretion in vitro after short- and long-term exposure to fatty acids. Our results show that GPR40 KO mice have essentially normal glucose tolerance and insulin secretion in response to glucose. Insulin secretion in response to Intralipid was reduced by ∼50%. In isolated islets, insulin secretion in response to glucose and other secretagogues was unaltered, but fatty acid potentiation of insulin release was markedly reduced. The Gαq/11 inhibitor YM-254890 dose-dependently reduced palmitate potentiation of glucose-induced insulin secretion. Islets from GPR40 KO mice were as sensitive to fatty acid inhibition of insulin secretion upon prolonged exposure as islets from wild-type animals. We conclude that GPR40 contributes approximately half of the full acute insulin secretory response to fatty acids in mice but does not play a role in the mechanisms by which fatty acids chronically impair insulin secretion.

1 July 2006 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
TMTonya L. Martin
Tonya L. Martin
TAThierry Alquier
Thierry Alquier
KAKenji Asakura
Kenji Asakura
NFNoboru Furukawa
Noboru Furukawa
FPFrederic Preitner
Frederic Preitner
BKBarbara B. Kahn
Barbara B. Kahn
AMP-activated protein kinase (AMPK) is a key regulator of cellular energy balance and of the effects of leptin on food intake and fatty acid oxidation. Obesity is usually associated with resistance to the effects of leptin on food intake and body weight. To determine whether diet-induced obesity (DIO) impairs the AMPK response to leptin in muscle and/or hypothalamus, we fed FVB mice a high fat (55%) diet for 10–12 weeks. Leptin acutely decreased food intake by ∼30% in chow-fed mice. DIO mice tended to eat less, and leptin had no effect on food intake. Leptin decreased respiratory exchange ratio in chow-fed mice indicating increased fatty acid oxidation. Respiratory exchange ratio was low basally in high fat-fed mice, and leptin had no further effect. Leptin (3 mg/kg intraperitoneally) increased α2-AMPK activity 2-fold in muscle in chow-fed mice but not in DIO mice. Leptin decreased acetyl-CoA carboxylase activity 40% in muscle from chow-fed mice. In muscle from DIO mice, acetyl-CoA carboxylase activity was basally low, and leptin had no further effect. In paraventricular, arcuate, and medial hypothalamus of chow-fed mice, leptin inhibited α2-AMPK activity but not in DIO mice. In addition, leptin increased STAT3 phosphorylation 2-fold in arcuate of chow-fed mice, but this effect was attenuated because of elevated basal STAT3 phosphorylation in DIO mice. Thus, DIO in FVB mice alters α2-AMPK in muscle and hypothalamus and STAT3 in hypothalamus and impairs further effects of leptin on these signaling pathways. Defective responses of AMPK to leptin may contribute to resistance to leptin action on food intake and energy expenditure in obese states.

1 July 2015 in Molecular Endocrinology
Verified
Journal Article
Open access
PDF file
Medha PriyadarshiniMedha Priyadarshini
Medha Priyadarshini
SVStephanie R. Villa
Stephanie R. Villa
MFMiles Fuller
Miles Fuller
BWBarton Wicksteed
Barton Wicksteed
CMCharles R. Mackay
Charles R. Mackay
BLBrian T. Layden
Brian T. Layden
G protein-coupled receptors have been well described to contribute to the regulation of glucose-stimulated insulin secretion (GSIS). The short-chain fatty acid-sensing G protein-coupled receptor, free fatty acid receptor 2 (FFAR2), is expressed in pancreatic β-cells, and in rodents, its expression is altered during insulin resistance. Thus, we explored the role of FFAR2 in regulating GSIS. First, assessing the phenotype of wild-type and Ffar2−/− mice in vivo, we observed no differences with regard to glucose homeostasis on normal or high-fat diet, with a marginally significant defect in insulin secretion in Ffar2−/− mice during hyperglycemic clamps. In ex vivo insulin secretion studies, we observed diminished GSIS from Ffar2−/− islets relative to wild-type islets under high-glucose conditions. Further, in the presence of acetate, the primary endogenous ligand for FFAR2, we observed FFAR2-dependent potentiation of GSIS, whereas FFAR2-specific agonists resulted in either potentiation or inhibition of GSIS, which we found to result from selective signaling through either Gαq/11 or Gαi/o, respectively. Lastly, in ex vivo insulin secretion studies of human islets, we observed that acetate and FFAR2 agonists elicited different signaling properties at human FFAR2 than at mouse FFAR2. Taken together, our studies reveal that FFAR2 signaling occurs by divergent G protein pathways that can selectively potentiate or inhibit GSIS in mouse islets. Further, we have identified important differences in the response of mouse and human FFAR2 to selective agonists, and we suggest that these differences warrant consideration in the continued investigation of FFAR2 as a novel type 2 diabetes target.

1 September 2008 in Diabetes
Verified
Journal Article
Open access
Melkam Alamerew KebedeMelkam Alamerew Kebede
Melkam Alamerew Kebede
TAThierry Alquier
Thierry Alquier
MLMartin G. Latour
Martin G. Latour
MSMeriem Semache
Meriem Semache
CTCaroline Tremblay
Caroline Tremblay
VPVincent Poitout
Vincent Poitout
OBJECTIVE—The G-protein–coupled receptor GPR40 is expressed in pancreatic β-cells and is activated by long-chain fatty acids. Gene deletion studies have shown that GPR40 mediates, at least in part, fatty acid–amplification of glucose-induced insulin secretion (GSIS) but is not implicated in GSIS itself. However, the role of GPR40 in the long-term effects of fatty acids on insulin secretion remains controversial. This study aimed to test the hypothesis that GPR40 plays a role in insulin secretion after high-fat feeding. RESEARCH DESIGN AND METHODS—GPR40 knockout (KO) mice on a C57BL/6 background and their wild-type (WT) littermates were fed a high-fat diet (HFD) for 11 weeks. Glucose tolerance, insulin tolerance, and insulin secretion in response to glucose and Intralipid were assessed during the course of the diet period. RESULTS—GPR40 KO mice had fasting hyperglycemia. They became as obese, glucose intolerant, and insulin resistant as their WT littermates given HFD and developed a similar degree of liver steatosis. Their fasting blood glucose levels increased earlier than those of control mice during the course of the HFD. The remarkable increase in insulin secretory responses to intravenous glucose and Intralipid seen in WT mice after HFD was of much lower magnitude in GPR40 KO mice. CONCLUSIONS—GPR40 plays a role not only in fatty acid modulation of insulin secretion, but also in GSIS after high-fat feeding. These observations raise doubts on the validity of a therapeutic approach based on GPR40 antagonism for the treatment of type 2 diabetes.